CTSC and bronchiectasis: More recently, a trial of Brensocatib (an oral reversible inhibitor of dipeptidyl peptidase 1 (DPP-1), an enzyme responsible for the activation of neutrophil serine proteases) showed a reduction sputum neutrophil proteinases and improvements in clinical outcomes in bronchiectasis (150).